• IDEX Corporation has already reported first-quarter 2026 results, posting sales of US$886.9 million and net income of US$120 million, while continuing long-running capital returns with a buyback program that has retired 19,574,272 shares for about US$1.68 billion since 2008.
• The quarter highlighted strong momentum in the Health & Science Technologies segment, record orders, margin expansion, raised full-year growth and earnings guidance, and ongoing cash returns to shareholders through share repurchases and dividends.
• Now we’ll examine how the raised full-year guidance and Health & Science Technologies strength influence IDEX’s existing investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

IDEX Investment Narrative Recap

IDEX’s story still rests on its ability to compound earnings by serving mission critical applications while keeping margins resilient. The latest quarter reinforced that narrative, with Health & Science Technologies (HST) leading growth and management raising full year guidance. Near term, the key catalyst is whether strong HST demand and record orders translate into sustained margin strength, while the biggest risk remains that cyclical or policy driven shocks could disrupt orders and make near term earnings more volatile. The new results do not materially change that risk balance.

The most relevant update here is the raised 2026 organic growth and adjusted EPS guidance, supported by 5% organic sales growth, 10% organic order growth, and 11% HST revenue growth in Q1 2026. That guidance sits alongside continued cash returns, including US$96.8 million of buybacks in early 2026 and an established dividend record, which together show how closely the catalyst of HST led growth is tied to IDEX’s ability to keep converting demand in semiconductors, data centers, and space and defense into cash flow.

Yet investors should be aware that, despite strong HST demand and record orders, customer hesitancy on larger projects could still...

IDEX's narrative projects $3.9 billion revenue and $650.9 million earnings by 2029. This requires 4.5% yearly revenue growth and about a $167.7 million earnings increase from $483.2 million today.

Uncover how IDEX's forecasts yield a $222.71 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Three members of the Simply Wall St Community currently estimate IDEX’s fair value between US$180 and about US$259.66, showing how far apart individual views can be. Against that wide range, the renewed focus on HST driven growth and raised 2026 guidance sits beside ongoing concerns about policy uncertainty and order volatility, so it makes sense to compare several of these perspectives before forming your own view.

Explore 3 other fair value estimates on IDEX - why the stock might be worth as much as 21% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your IDEX research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free IDEX research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEX's overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Find 51 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.